- Home
- IMCR vs VERA Comparison
IMCR vs VERA Comparison
Compare IMCR & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- VERA
- Stock Information
- Founded
- IMCR 2008
- VERA 2016
- Country
- IMCR United Kingdom
- VERA United States
- Employees
- IMCR N/A
- VERA N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- IMCR Health Care
- VERA Health Care
- Exchange
- IMCR Nasdaq
- VERA Nasdaq
- Market Cap
- IMCR 1.7B
- VERA 2.5B
- IPO Year
- IMCR 2021
- VERA 2021
- Fundamental
- Price
- IMCR $32.93
- VERA $42.01
- Analyst Decision
- IMCR Buy
- VERA Strong Buy
- Analyst Count
- IMCR 14
- VERA 9
- Target Price
- IMCR $74.75
- VERA $53.56
- AVG Volume (30 Days)
- IMCR 267.8K
- VERA 683.6K
- Earning Date
- IMCR 11-05-2024
- VERA 11-07-2024
- Dividend Yield
- IMCR N/A
- VERA N/A
- EPS Growth
- IMCR N/A
- VERA N/A
- EPS
- IMCR N/A
- VERA N/A
- Revenue
- IMCR $280,914,000.00
- VERA N/A
- Revenue This Year
- IMCR $25.60
- VERA N/A
- Revenue Next Year
- IMCR $10.63
- VERA N/A
- P/E Ratio
- IMCR N/A
- VERA N/A
- Revenue Growth
- IMCR 27.95
- VERA N/A
- 52 Week Low
- IMCR $29.72
- VERA $9.68
- 52 Week High
- IMCR $76.98
- VERA $50.78
- Technical
- Relative Strength Index (RSI)
- IMCR 52.76
- VERA 52.57
- Support Level
- IMCR $31.10
- VERA $39.22
- Resistance Level
- IMCR $35.47
- VERA $50.00
- Average True Range (ATR)
- IMCR 1.49
- VERA 2.41
- MACD
- IMCR 0.17
- VERA 0.24
- Stochastic Oscillator
- IMCR 51.98
- VERA 28.53
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.